Medivir AB MVR-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 9:19 AM CEST
0.659quote price arrow up+0.024 (+3.78%)
52 week range
0.64 - 1.13
Loading...
  • Open0.659
  • Day High0.659
  • Day Low0.659
  • Prev Close0.70
  • 52 Week High1.13
  • 52 Week High Date08/17/21
  • 52 Week Low0.64
  • 52 Week Low Date05/13/22

Key Stats

  • Market Cap39.94M
  • Shares Out55.74M
  • 10 Day Average Volume30
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-29.44

KEY STATS

  • Open0.659
  • Day High0.659
  • Day Low0.659
  • Prev Close0.70
  • 52 Week High1.13
  • 52 Week High Date08/17/21
  • 52 Week Low0.64
  • 52 Week Low Date05/13/22
  • Market Cap39.94M
  • Shares Out55.74M
  • 10 Day Average Volume30
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-29.44

RATIOS/PROFITABILITY

  • EPS (TTM)-0.15
  • P/E (TTM)-4.39
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Medivir AB

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in...
Uli Hacksell Ph.D.
Independent Chairman of the Board
Jens Lindberg
Chief Executive Officer
Christina Herder Ph.D.
Chief Operating Officer, Executive Vice President
Magnus Christensen
Chief Financial Officer
Malene Jensen
Vice President - Clinical Development
Address
Lunastigen 5, 2 tr
Huddinge
141 22
Sweden